Mundipharma and CorMedix have unveiled a win for their antifungal drug Rezzayo at preventing invasive fungal diseases in patients receiving allogeneic hematopoietic stem cell transplants (HSCT). In ...
The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal-free survival at Day 90 Study showed favourable benefit for toxicity-related discontinuations ...
CAMBRIDGE, England--(BUSINESS WIRE)--As the European distributor of Invokana ® (canagliflozin) and Vokanamet ® (canagliflozin and metformin), Mundipharma welcomes the publication of the first KDIGO ...
The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal-free survival at Day 90 Study showed favourable benefit for toxicity-related discontinuations ...
Mundipharma today announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO ® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results